Get the Stockscreener App
1,038.27
2.27%
23.06
After Hours:
1042.00
3.73
+0.36%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,038.27, with a volume of 3.59M.
It is up +2.27% in the last 24 hours and down -3.95% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,015.21
Open:
$1024.87
24h Volume:
3.59M
Relative Volume:
1.05
Market Cap:
$929.27B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
45.23
EPS:
22.9554
Net Cash Flow:
$6.44B
1W Performance:
+1.71%
1M Performance:
-3.95%
6M Performance:
+62.37%
1Y Performance:
+18.94%
1-Day Range:
$1,012.00
$1,059.84
1-Week Range:
$1,012.00
$1,106.94
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,038.27 | 908.63B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
244.55 | 580.30B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
227.50 | 390.40B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.52 | 317.44B | 58.07B | 9.40B | 9.87B | 3.0115 |
|
NVS
Novartis Ag Adr
|
161.18 | 305.42B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision - Reuters
ELI LILLY & Co SEC 10-K Report - TradingView
Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market - Benzinga
Eli Lilly Stock (LLY) Gets New ‘Buy Rating’ After Strong Earnings - TipRanks
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift - PharmaVoice
Eli Lilly and Company $LLY Stock Position Increased by Varma Mutual Pension Insurance Co - MarketBeat
How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report - Nasdaq
Savvy Advisors Inc. Has $7.36 Million Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St.
Eli Lilly and Company (NYSE:LLY) Stock Rating Upgraded by Freedom Capital - MarketBeat
Eli Lilly Extends Lead in Weight-Loss Drug Market - AD HOC NEWS
Fund Update: 382,112 ELI LILLY (LLY) shares added to PARNASSUS INVESTMENTS, LLC portfolio - Quiver Quantitative
Illinois Municipal Retirement Fund Sells 1,002 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. - Yahoo Finance
Atria Investments Inc Has $30.79 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Is Eli Lilly and Company (NYSE:LLY) Strengthening its Position In S&P 500 Futures - Kalkine Media
Eli Lilly Leadership Receives Stock Awards Amid Strong Growth Forecast - AD HOC NEWS
Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline - Insider Monkey
7th Circ. Mulls Expiration Date Of Teva, Eli Lilly Patent Deal - Law360
Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials - Bloomberg.com
Top Analyst Reports for Eli Lilly, Marriott & Fortinet - TradingView
Robust Demand for Eli Lilly and Company (LLY)'s Obesity and Diabetes Treatments Drives Strong Investor Sentiment - Finviz
Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment - Yahoo Finance
3 Reasons to Buy Eli Lilly Stock - Yahoo Finance
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly - Stocktwits
Ex-Dividend Reminder: Bio-Techne, 3M and Eli Lilly - Nasdaq
Eli Lilly and Company $LLY Shares Bought by Westbourne Investments Inc. - MarketBeat
Mechanics Financial Corp Has $1.98 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Position Raised by Madison Asset Management LLC - MarketBeat
Stratos Wealth Partners LTD. Grows Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Jensen Investment Management Inc. - MarketBeat
The Top 5 Analyst Questions From Eli Lilly's Q4 Earnings Call - Finviz
CICC Adjusts Price Target on Eli Lilly and Co. to $1,107 From $1,060, Maintains Neutral Rating - marketscreener.com
Cibc World Market Inc. Buys 49,634 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly buys Orna Therapeutics for US$2.4bn - Health Tech World
Lilly's bowel disease drug gets approval in China - marketscreener.com
Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued - Yahoo Finance
Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitisCo statement - marketscreener.com
Fisher Asset Management Boosts Eli Lilly Stake by 153K Shares - TipRanks
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. - Yahoo Finance
This Week's Healthcare Earnings: Lilly, Cigna And More - Law360
Eli Lilly expansion poised to reshape Lehigh Valley housing market - WFMZ.com
Eli Lilly stock upgraded to Buy at Freedom Capital on strong growth outlook - Investing.com Canada
Beyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System DealsGEN - GEN - Genetic Engineering and Biotechnology News
LLY Stock Quote Price and Forecast - CNN
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Hengrui, Kailera phase 2 obesity pill results could pressure Eli Lilly's orforglipron - Seeking Alpha
LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal - The Globe and Mail
Lilly’s ENLIGHTEN-4 Trial Targets Knee Osteoarthritis Pain in Overweight Patients - TipRanks
Eli Lilly stock price target maintained at $1,250 by UBS on orforglipron outlook - Investing.com
Innovent-Lilly $8.5B deal signals new China inflection point - BioWorld MedTech
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):